GCS
Inhibitory Selectivity
GCS Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S9728New |
BSO (L-Buthionine-(S,R)-sulfoximine)BSO (L-Buthionine-(S,R)-sulfoximine, L-Buthionine sulfoximine) is a cell-permeable, potent, fast acting and irreversible inhibitor of g-glutamylcysteine synthetase (γ-glutamylcysteine synthetase, γ-GCS) and depletes cellular glutathione levels. The IC50 of BSO on melanoma, breast and ovarian tumor specimens are 1.9 μM, 8.6 μM, and 29 μM, respectively. |
||
| S7852 |
EliglustatEliglustat (GENZ-112638) inhibits glucosylceramide synthase(GCS) (IC50=20 nM in intact MDCK cells), thus reducing the load of glucosylceramide influx into the lysosome. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S9728New |
BSO (L-Buthionine-(S,R)-sulfoximine)BSO (L-Buthionine-(S,R)-sulfoximine, L-Buthionine sulfoximine) is a cell-permeable, potent, fast acting and irreversible inhibitor of g-glutamylcysteine synthetase (γ-glutamylcysteine synthetase, γ-GCS) and depletes cellular glutathione levels. The IC50 of BSO on melanoma, breast and ovarian tumor specimens are 1.9 μM, 8.6 μM, and 29 μM, respectively. |
||
| S7852 |
EliglustatEliglustat (GENZ-112638) inhibits glucosylceramide synthase(GCS) (IC50=20 nM in intact MDCK cells), thus reducing the load of glucosylceramide influx into the lysosome. |
